Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed 78 childhood trichotillomania cases and found the scalp was the primary site for hair pulling, with comorbid psychiatric disorders present in many cases.

This study found that 5-α reductase inhibitors and neuropsychiatric medications were most frequently reported for erectile dysfunction in a national pharmacovigilance database from 2010 to 2020.

This study formulated a polyherbal shampoo from plant extracts, finding it showed effective antifungal properties against dandruff-causing agents like Malassezia species while providing protective and conditioning effects on hair cuticles, indicating its potential as a natural alternative for dandruff management.

This study found that a formulated polyherbal shampoo demonstrated effective antifungal properties against dandruff-causing fungi, with smooth, intact hair cuticles after treatment, suggesting it may serve as a safe, natural alternative for managing dandruff.

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.

In this study, female rats given high doses of testosterone showed decreased endometrial thickness and lower mRNA levels of components in the LIF signalling pathway, indicating that excessive testosterone may negatively impact endometrial receptivity and potentially affect fertility.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

This case study observed that in four middle-aged men with ejaculation disorders, therapy with human chorionic gonadotropin (hCG) alone or combined with recombinant follicle-stimulating hormone (rFSH) improved sexual desire, semen volume, and various other symptoms, although some experienced elevated estradiol levels and hair loss.

This study found that 5-alpha reductase inhibitors had the highest association with erectile dysfunction reports among medications analyzed in the FDA's national pharmacovigilance database.

Hair loss is a common side effect of hormone treatments for cancer.

This study reports that hair fibers degrade most in acidic sandy clay, while silicone oil treatment is effective for conserving various hair types and artifacts.

This chapter reviews drugs affecting blood coagulation and details the increased hemorrhage risk associated with warfarin interactions, liver disease, heart failure, and antiphospholipid antibodies but reports no new clinical results.

In this study, finasteride use in men with androgenetic alopecia was not associated with increased reports of sexual dysfunction compared to non-users, suggesting that finasteride does not cause sexual dysfunction in this context.

In this study, the authors reported no significant difference in sexual dysfunction between finasteride users and non-users among men with androgenetic alopecia, suggesting that finasteride does not cause sexual dysfunction. This finding aligns with other large survey-based studies.

This study found that Ecklonia cava polyphenols increased human dermal papilla cell proliferation and extended hair shaft length in vitro and ex vivo, suggesting potential as a therapeutic candidate for hair loss.

This study suggests that finasteride may reduce the aggressiveness and invasion of prostate tumors, with effects potentially differing based on the androgen responsiveness of the patient's prostate cells.

This review discusses potential therapeutic options for frontal fibrosing alopecia by exploring distinct signaling pathways and cellular players, but reports no new clinical findings and emphasizes the need for further trials.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This retrospective cohort study found that patients using 5α-reductase inhibitors had reduced bladder cancer-related mortality compared to nonusers, with no significant effect on bladder cancer recurrence or upper tract urothelial carcinoma mortality.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This review highlights the traditional use and potential therapeutic activities of Asiasari Radix in drug discovery, but it reports no new clinical results.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

This study concluded that administering 5-alpha reductase inhibitors before photoselective vaporization of the prostate increased hemoglobin change, lasing time, and energy required during the procedure compared to controls.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.